| Literature DB >> 32728711 |
Martijn G Ten Berge1,2, Naomi Beck1,2, Willem Hans Steup3, Ad F T M Verhagen4, Thomas J van Brakel5, Wilhelmina H Schreurs6, Michel W J M Wouters2,7.
Abstract
OBJECTIVES: Quality assessment is an important element in providing surgical cancer care. The main objective of this study was to develop a new composite measure 'textbook outcome', to evaluate and improve quality of surgical care for patients undergoing a resection for non-small-cell lung cancer (NSCLC).Entities:
Keywords: Clinical auditing; Non-small-cell lung cancer; Postoperative outcome; Surgery; Textbook outcome
Year: 2021 PMID: 32728711 PMCID: PMC7781522 DOI: 10.1093/ejcts/ezaa265
Source DB: PubMed Journal: Eur J Cardiothorac Surg ISSN: 1010-7940 Impact factor: 4.191
Figure 1:Diagram representing textbook outcome as composite measure of outcome parameters in patients undergoing surgery for non-small-cell lung cancer (2012–2016). Blue bar: percentage of outcome parameter; orange line: textbook outcome. ICU: intensive care unit.
Tumour and treatment characteristics of patients with textbook outcomes after surgery for non-small-cell lung cancer
| Textbook outcome | No textbook outcome |
| |
|---|---|---|---|
| ( | ( | ||
| Sex | |||
| Male | 720 (50.3) | 2339 (57.3) | <0.001 |
| Female | 710 (49.7) | 1744 (42.7) | |
| Age (years) | |||
| 20–59 | 329 (23) | 791 (19.4) | 0.003 |
| 60–69 | 561 (39.2) | 1573 (38.5) | |
| 70–79 | 472 (33) | 1459 (35.7) | |
| >80 | 68 (4.8) | 260 (6.4) | |
| ASA group | |||
| I–II | 1120 (78.3) | 3015 (73.8) | <0.001 |
| III–IV | 888 (21.7) | 1068 (26.2) | |
| Charlson score | |||
| 0 | 500 (35) | 1290 (31.6) | 0.055 |
| 1 | 412 (28.8) | 1207 (29.6) | |
| 2+ | 518 (36.2) | 1586 (38.8) | |
| Cardiac comorbidity | |||
| No | 1087 (76) | 2939 (72.0) | 0.003 |
| Yes | 343 (24) | 1144 (28) | |
| Pulmonary comorbidity | |||
| No | 989 (69.2) | 2525 (61.8) | <0.001 |
| Yes | 441 (30.8) | 1558 (38.2) | |
| Diabetes mellitus | |||
| No | 1252 (87.6) | 3533 (86.5) | 0.33 |
| Yes | 178 (1.4) | 550 (13.5) | |
| Neurological comorbidity | |||
| No | 1223 (85.5) | 3478 (85.2) | 0.099 |
| Yes | 207 (14.5) | 605 (14.8) | |
| Thrombotic comorbidity | |||
| No | 1382 (96.6) | 3950 (96.7) | 0.74 |
| Yes | 48 (3.4) | 133 (3.3) | |
| Vascular comorbidity | |||
| No | 908 (63.5) | 2490 (61) | 0.097 |
| Yes | 522 (36.5) | 1593 (39) | |
| DLCO | |||
| >40% | 700 (49) | 2076 (50.8) | <0.001 |
| <40% | 14 (1) | 69 (1.7) | |
| Missing | 716 (50.1) | 1938 (47.5) | |
| FEV1 | |||
| >40% | 456 (31.9) | 1511 (37) | <0.002 |
| <40% | 8 (0.6) | 40 (1) | |
| Missing | 966 (67.6) | 2532 (62) | |
| Clinical stage | |||
| IA | 586 (41.0) | 1657 (40.6) | 0.96 |
| IB | 319 (22.3) | 934 (22.9) | |
| IIA | 233 (16.3) | 647 (15.8) | |
| IIB | 182 (12.7) | 513 (12.6) | |
| IIIA | 110 (7.7) | 332 (8.1) | |
| Previous thoracic surgery | |||
| No | 1401 (98) | 4013 (98.3) | 0.44 |
| Yes | 29 (2) | 70 (1.7) | |
| Resection | |||
| Pneumonectomy | 118 (8.3) | 281 (6.9) | 0.099 |
| Bilobectomy | 74 (5.2) | 254 (6.2) | |
| Lobectomy | 1201 (84.4) | 3465 (84.9) | |
| Segmental resection | 37 (2.6) | 83 (2) | |
| Approach | |||
| Video-assisted thoracoscopic surgery | 1009 (70.6) | 2762 (67.6) | <0.001 |
| Thoracotomy | 379 (26.5) | 1156 (28.3) | |
| Robot-assisted thoracic surgery | 38 (2.7) | 57 (1.4) | |
| Missing | 4 (0.3) | 108 (2.6) | |
χ 2 test for trend.
TNM 7th edition.
ASA: American Society of Anesthesiologists; DLCO: diffusing capacity of the lung for carbon monoxide (preoperative); FEV1: forced expired volume in 1 s (preoperative).
Multivariable logistic regression analysis of textbook outcome
| OR | 95% confidence interval |
| ||
|---|---|---|---|---|
| Lower | Upper | |||
| Sex | ||||
| Male | REF | 0.001 | ||
| Female | 1.21 | 1.06 | 1.37 | |
| Age (years) | ||||
| 20–59 | REF | 0.016 | ||
| 60–69 | 0.87 | 0.74 | 1.03 | |
| 70–79 | 0.83 | 0.69 | 0.99 | |
| >80 | 0.62 | 0.01 | 0.85 | |
| ASA score | ||||
| I–II | REF | 0.026 | ||
| III–IV | 0.86 | 0.73 | 0.99 | |
| Cardiac comorbidity | ||||
| No | REF | 0.090 | ||
| Yes | 0.88 | 0.76 | 1.02 | |
| Pulmonary comorbidity | ||||
| No | REF | 0.001 | ||
| Yes | 0.75 | 0.65 | 0.86 | |
| Diabetes mellitus | ||||
| No | REF | |||
| Yes | 1.03 | 0.89 | 1.25 | 0.74 |
| DLCO | ||||
| >40% | REF | 0.060 | ||
| ≤40% | 0.56 | 0.32 | 1.02 | |
| Missing | 0.89 | 0.75 | 1.05 | |
| FEV1 | ||||
| >40% | REF | 0.039 | ||
| ≤40% | 0.69 | 0.32 | 1.49 | |
| Missing | 1.19 | 1.02 | 1.37 | |
| Previous thoracic surgery | ||||
| No | REF | 0.43 | ||
| Yes | 1.20 | 0.76 | 1.90 | |
| Clinical stage | ||||
| IA | REF | 0.78 | ||
| IB | 1.01 | 0.89 | 1.19 | |
| IIA | 1.06 | 0.87 | 1.27 | |
| IIB | 1.13 | 0.88 | 1.38 | |
| IIIA | 1.06 | 0.82 | 1.35 | |
ASA: American Society of Anesthesiologists; DLCO: Diffusing capacity for carbon monoxide; FEV1: forced expiratory volume in 1 s; OR: odds ratio.
Figure 2:(A) Funnel plot presenting hospital variation: case-mix adjusted textbook outcome rates for individual hospitals (2012–2016). (B) Funnel plot presenting hospital variation: case-mix adjusted textbook outcome rates for individual hospitals without sufficient lymph node dissection (2012–2016). Blue dot: hospital; 95% CI: 95% confidence interval; NSCLC: non-small-cell lung cancer.